Skip to main content Accessibility help
×
Home

Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?

  • J. M. COLLARD (a1), Z. MAMAN (a2), A. ABANI (a2), H. B. MAINASARA (a1), S. DJIBO (a1), H. YACOUBA (a2), R. MAITOURNAM (a2), F. SIDIKOU (a1), P. NICOLAS (a3), J. ROCOURT (a1) and J. F. JUSOT (a1)...

Summary

The 2009 meningitis season in Niger was characterized by an early onset, beginning in the very first weeks of the year and peaking from the 12th to the 15th week with 5655 clinical cases over the 4 weeks. From 1 January 2009 to 28 June 2009 (week 26), a total of 13 733 clinical cases of meningitis were reported to the national epidemiological surveillance system with a case-fatality rate of 4·2%. During the season 25 of the 42 health districts reached the epidemic threshold and 11 the alert threshold. Reactive mass vaccination campaigns involving a total of 5 166 741 doses of the polysaccharide meningococcal bivalent (A+C) vaccine progressively controlled the outbreak in most parts of the country. A total of 3755 cerebrospinal fluid samples representing 28·1% of the suspected meningitis cases were analysed. Serogroup A meningococci were the causative agent in 97·5% of the meningococcal cases. Multi-locus sequence typing of 26 meningococal serogroup A strains showed 25 sequence type (ST)7 and one ST2859, both sequence types belonging to the ST5 clonal complex (CC5) of subgroup III. This is the largest epidemic observed in Niger since those of 1995–1996 (59 948 notified cases) and 2000 (14 633 notified cases).

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Microbiological and epidemiological investigation of the Neisseria meningitidis serogroup A epidemic in Niger in 2009: last wave before the introduction of the serogroup A meningococcal conjugate vaccine?
      Available formats
      ×

Copyright

Corresponding author

*Author for correspondence: Dr J. M. Collard, 634 Boulevard de la Nation YN034, PO Box 10887, Niamey, Niger. (Email: jmcollard@cermes.org)

References

Hide All
1.Chanteau, S, et al. Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in Niger. Transactions of the Royal Society of Tropical Medicine and Hygiene 2006; 100: 677680.
2.WHO. Control of epidemic meningococcal disease. WHO practical guidelines, 2nd edn. WHO/EMC/BAC/98.3:1. Geneva: World Health Organization, 1998.
3.Nicolas, P, et al. Clonal expansion of sequence type (ST-)5 and emergence of ST-7 in serogroup A meningococci, Africa. Emerging Infections and Diseases 2001; 7: 849854.
4.Caughant, DA, Nicolas, P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine 2007; 25 (Suppl. 1): A8–11.
5.Nicolas, P, et al. Molecular epidemiology of Neisseria meningitidis isolated in the African meningitis belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. Journal of Clinical Microbiology 2005; 43: 51295135.
6.Teyssou, R, Muros-Le Rouzic, E. Meningitis epidemics in Africa: a brief overview. Vaccine 2007; 25 (Suppl. 1): A3–7.
7.Nicolas, P, et al. Activity report 2008. Meningococcal Unit, WHO Collaborating Centre, Marseille, France, 2009, 23 pp.
8.World Health Organization. Meningitis in Chad, Niger and Nigeria: 2009 epidemic season. Weekly Epidemiological Record 2010; 85: 4763.
9.Anon. Epidemiological situation of week 25 (15–21 June 2009). MDSC Meningitis Weekly Bulletin 2009 (http://www.who.int/csr/disease/meningococcal/BulletinMeningite2009_S25.pdf) Accessed 26 August 2009.
10.Yaro, S, et al. Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso. Clinical Infectious Diseases 2006; 43: 693700.
11.LaForce, MF, et al. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine 2009; 27 (Suppl. 2): B13–19.
12.Campbell, H, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009; 27 (Suppl. 2): B20–29.

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed